Cancer News and Research

Latest Cancer News and Research

Exploring whether chemotherapy disrupts biological clock in the brain to impair circadian rhythms

During and after chemotherapy, nearly half of cancer patients endure circadian rhythm disruptions, which worsens treatment side effects.

9 Sep 2025

‘Rogue’ DNA rings identified as drivers of aggressive brain cancer

An international team of scientists has revealed how rogue rings of DNA that float outside of our chromosomes – known as extrachromosomal DNA, or ecDNA – can drive the growth of a large proportion of glioblastomas, the most common and aggressive adult brain cancer.

9 Sep 2025

Cancer cells found to use ketones as alternate fuel for growth

When it comes to their survival, cancer cells have a host of backup plans.

8 Sep 2025

Smart material delivers drugs in response to arthritis flare-ups

Researchers have developed a material that can sense tiny changes within the body, such as during an arthritis flare-up, and release drugs exactly where and when they are needed.

8 Sep 2025

Why smartphone use on the toilet may increase hemorrhoid risk

Adults using smartphones on the toilet spent significantly more time seated and had 46% higher odds of hemorrhoids on colonoscopy. The cross-sectional study suggests prolonged sitting, not straining, may be the key driver of hemorrhoid risk.

8 Sep 2025

Common diabetes drug metformin cuts long covid risk by 64 percent in UK study

A large UK-based retrospective cohort study found that initiating metformin within 90 days of COVID-19 diagnosis reduced the risk of Long COVID by 64% in overweight and obese adults. The findings suggest metformin may offer a low-cost preventive option pending confirmation from randomized trials.

8 Sep 2025

Mushrooms deliver nutrition medicine and sustainability solutions in one package

This Food Science & Nutrition review highlights mushrooms as nutrient-rich functional foods packed with bioactive compounds that support human health. It explores their therapeutic, industrial, and environmental applications, from disease prevention and drug discovery to bioremediation and bioenergy.

8 Sep 2025

New strategy for difficult-to-treat mesothelioma: Immunotherapy and ctDNA insights

People with operable diffuse pleural mesothelioma may benefit from immunotherapy before and after surgery, based on results of a clinical trial exploring the sequence of treatment and the role of surgery for this difficult to treat cancer.

8 Sep 2025

Many patients undergoing surgery for early-stage cancer continue or start opioid prescriptions

New research indicates that many patients who undergo surgery with the intent to cure early-stage cancer continue or start opioid prescriptions in the year following surgery.

8 Sep 2025

New technology could make MRI scanners cost-effective and more accessible

Revolutionary new technology could make MRI scanners cost effective, more widely available to local communities and help save lives, thanks to a pioneering collaboration between the University of Sheffield and GE HealthCare.

8 Sep 2025

Tarlatamab and anti-PD-L1 therapy combination demonstrates manageable safety profile in first-line ES-SCLC

Clinical data presented today demonstrates the combination of tarlatamab with anti-PD-L1 therapy as first-line maintenance has an acceptable safety profile and resulted in unprecedented overall survival in patients with extensive-stage small cell lung cancer (ES-SCLC).

8 Sep 2025

HypoRT with concurrent chemotherapy reduces treatment time and toxicity for patients with LS-SCLC

A multi-center, randomized phase III trial has found that a three-week hypofractionated radiotherapy (HypoRT) schedule with concurrent chemotherapy provides similar survival outcomes and reduced toxicity compared to the standard six-week conventional fractionated radiotherapy (ConvRT) schedule for patients with limited-stage small cell lung cancer (LS-SCLC).

8 Sep 2025

Study could pave the way for simple blood test to diagnose Alzheimer's disease

In a landmark study of Hispanic and Latino adults, researchers at University of California San Diego School of Medicine have identified a link between self-reported cognitive decline and blood-based biomarkers, which could pave the way for a simple blood test to help diagnose Alzheimer's disease and related dementias.

8 Sep 2025

Adjuvant chemo-immunotherapy may benefit patients with resected stage IB–IIIA NSCLC, trial suggests

Interim results from the NADIM ADJUVANT Phase III trial, led by the Spanish Lung Cancer Group (GECP), suggest that adjuvant chemo-immunotherapy may reduce the risk of recurrence in patients with completely resected stage IB–IIIA non-small cell lung cancer (NSCLC) while maintaining an acceptable safety profile.

8 Sep 2025

Ifinatamab deruxtecan may benefit patients with recurrent or progressive ES-SCLC

Patients diagnosed with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) may benefit from treatment with ifinatamab deruxtecan (I-DXd), a B7-H3–directed antibody–drug conjugate, according to data presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.

8 Sep 2025

Nicotine pouch use may be a step toward reducing more dangerous forms of tobacco

As lawmakers and public health experts debate the safety of nicotine pouches, researchers from Rutgers Health found that for now, most adults that use these products also have a history of tobacco use and may be choosing these products as a possible step toward reducing or quitting more dangerous forms of nicotine delivery.

8 Sep 2025

Osimertinib plus chemotherapy offers overall survival advantage for patients with EGFR-mutated advanced NSCLC

Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus chemotherapy significantly improves OS compared to osimertinib monotherapy in patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC).

8 Sep 2025

New antibody-drug conjugate iza-bren may offer promising treatment option for EGFR-mutated NSCLC patients

A novel antibody-drug conjugate (ADC), iza-bren (BL-B01D1), demonstrated encouraging safety and efficacy results in previously treated patients with EGFR-mutated non-small cell lung cancer (NSCLC), according to findings presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC).

8 Sep 2025

Ivonescimab plus chemotherapy provides survival benefit for difficult-to-treat NSCLC patients

Adding ivonescimab, a first-in-class bispecific antibody targeting both PD-1 and VEGF, to chemotherapy significantly prolonged progression-free survival (PFS) compared to chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations whose disease progressed on third-generation EGFR tyrosine kinase inhibitors (TKIs).

8 Sep 2025

Study validates deep learning model for predicting future lung cancer risk in Black population

A new study presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC) validates the use of Sybil, a deep learning artificial intelligence model, for predicting future lung cancer risk in a predominantly Black population.

8 Sep 2025

Previous
1
...
48
49
50
51
52
53
54
...
4603
Next

Cancer News and Research

Latest Cancer News and Research

Exploring whether chemotherapy disrupts biological clock in the brain to impair circadian rhythms

‘Rogue’ DNA rings identified as drivers of aggressive brain cancer

Cancer cells found to use ketones as alternate fuel for growth

Smart material delivers drugs in response to arthritis flare-ups

Why smartphone use on the toilet may increase hemorrhoid risk

Common diabetes drug metformin cuts long covid risk by 64 percent in UK study

Mushrooms deliver nutrition medicine and sustainability solutions in one package

New strategy for difficult-to-treat mesothelioma: Immunotherapy and ctDNA insights

Many patients undergoing surgery for early-stage cancer continue or start opioid prescriptions

New technology could make MRI scanners cost-effective and more accessible

Tarlatamab and anti-PD-L1 therapy combination demonstrates manageable safety profile in first-line ES-SCLC

HypoRT with concurrent chemotherapy reduces treatment time and toxicity for patients with LS-SCLC

Study could pave the way for simple blood test to diagnose Alzheimer's disease

Adjuvant chemo-immunotherapy may benefit patients with resected stage IB–IIIA NSCLC, trial suggests

Ifinatamab deruxtecan may benefit patients with recurrent or progressive ES-SCLC

Nicotine pouch use may be a step toward reducing more dangerous forms of tobacco

Osimertinib plus chemotherapy offers overall survival advantage for patients with EGFR-mutated advanced NSCLC

New antibody-drug conjugate iza-bren may offer promising treatment option for EGFR-mutated NSCLC patients

Ivonescimab plus chemotherapy provides survival benefit for difficult-to-treat NSCLC patients

Study validates deep learning model for predicting future lung cancer risk in Black population

Understanding the DNA Damage Response in Innate Immunity eBook

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Newsletters you may be interested in